– GEMTESA® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – MARLBOROUGH, Mass., Dec. 23, 2024...

Latest results in Phase 1/2 studies show promise for two investigational treatments for patients with relapsed/refractory blood and bone marrow cancers Nuvisertib (TP-3654), an investigational...

Marking the third year, the Time To Go™ campaign features Holly Robinson Peete in conversation with real-life patients sharing about their experiences managing the disruptive condition of OAB...

Nuvisertib (TP-3654), an oral investigational highly selective PIM1 kinase inhibitor, is being evaluated in a Phase 1/2 study in patients with relapsed/refractory myelofibrosis Enzomenib...

MARLBOROUGH, Mass., September 23, 2024 – Sumitomo Pharma America, Inc. (SMPA) today announced that Kenton Stewart, Senior Vice President, Head of Sales and Market Access, has been promoted to...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a mixed lineage leukemia...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia – MARLBOROUGH, Mass., June 14, 2024 /PRNewswire

–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes–

–Data includes results from Phase 3 study of vibegron 75mg (GEMTESA) in men living with overactive bladder receiving pharmacological treatment for benign prostatic hyperplasia– MARLBOROUGH, Mass.,

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) and its U.S.-based subsidiary...

Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is now available for prescription in Canada for the...

In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate tablets 0.5 mg...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia, with Positive Preliminary Data Presented at...

–Time To Go™ Campaign Encourages People Experiencing Overactive Bladder (OAB) Symptoms to Talk to Their Healthcare Provider about Symptoms, Seek Diagnosis and Ask About GEMTESA® (Vibegron)–...

– ASH Preliminary Data Includes New Clinical Results in Relapsed or Refractory Myelofibrosis (TP-3654) and Relapsed or Refractory Acute Leukemia (DSP-5336) – CAMBRIDGE, Mass., Nov. 3, 2023...

Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland, GmbH ('SMPS') today announce that the European Commission ('EC') has granted...

– ORGOVYX is the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Approved for Advanced Prostate Cancer in Canada – MISSISSAUGA, Ontario, Oct. 23, 2023...

Sumitomo Pharma Canada, Inc. and Pfizer Canada today announced that Health Canada has granted a Notice of Compliance (NOC) for MYFEMBREE (Relugolix, estradiol and norethindrone acetate tablets)...

CAMBRIDGE, Mass., October 2, 2023 – Sumitomo Pharma America, Inc. (SMPA) today announced Ron Gimbel has been appointed as the Company’s new Chief Financial Officer. Mr. Gimbel, an industry...

Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') today announce that the Committee for Medicinal Products for...

–Vibegron Met Both Co-Primary Endpoints Demonstrating Statistically Significant Reductions in Daily Micturition and Urgency Episodes, Compared to Placebo at Week 12– –Vibegron Met All...

July 31, 2023 — Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) and Otsuka...

CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ — Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in...

MARLBOROUGH, Mass. & PRINCETON, N.J., April 26, 2023 8:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka)...

NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its wholly owned...